Literature DB >> 17270153

The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians.

Renato Scacchi1, Alessandro Pinto, Giuseppe Gambina, Aldo Rosano, Rosa Maria Corbo.   

Abstract

Recent observations support the hypothesis that inflammatory processes at the brain level may contribute to the pathogenesis of Alzheimer's disease (AD). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is involved in such processes, so we thought it interesting to study the Pro12Ala polymorphism in exon 2 of the gene in a sample of late-onset AD patients. We found that Ala genotypes were significantly overrepresented among octogenarian patients compared to controls (p=0.034). Using logistic regression we observed that carrying the Ala allele significantly increased by nearly two-fold the risk of developing AD in subjects 80 years or older (OR=1.98; 95% CI 1.03-3.80, p=0.04). Though this difference was borderline significant after correction for multiple comparisons, our results suggest a possible involvement of the PPAR-gamma gene in susceptibility to late-onset AD in octogenarians.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270153     DOI: 10.1016/j.brainres.2006.12.078

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Pro12Ala polymorphism in PPAR-gamma2 and dementia in Chinese nonagenarians/centenarians.

Authors:  Ji-Rong Yue; Bi-Rong Dong; Chang-Quan Huang; Zhen-Chan Lu; Hong-Mei Wu; Yan-Ling Zhang
Journal:  Age (Dordr)       Date:  2010-01-27

2.  The PPARG Pro12Ala Polymorphism and 20-year Cognitive Decline: Race and Sex Heterogeneity.

Authors:  Nancy A West; Jonathan V Tingle; Jeannette Simino; Elizabeth Selvin; Jan Bressler; Thomas H Mosley
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Apr-Jun       Impact factor: 2.703

Review 3.  PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

Authors:  Gary Landreth; Qingguang Jiang; Shweta Mandrekar; Michael Heneka
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

4.  The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study.

Authors:  Nancy A West; Mary N Haan; Hal Morgenstern
Journal:  Neurobiol Aging       Date:  2008-07-17       Impact factor: 4.673

5.  Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways.

Authors:  Larry A Denner; Jennifer Rodriguez-Rivera; Sigmund J Haidacher; Jordan B Jahrling; J Russ Carmical; Caterina M Hernandez; Yingxin Zhao; Rovshan G Sadygov; Jonathan M Starkey; Heidi Spratt; Bruce A Luxon; Thomas G Wood; Kelly T Dineley
Journal:  J Neurosci       Date:  2012-11-21       Impact factor: 6.167

Review 6.  Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma.

Authors:  Feng-Shiun Shie; Mary Nivison; Pei-Chien Hsu; Thomas J Montine
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

7.  Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia.

Authors:  Nobuto Shibata; Yumiko Motoi; Hiroyuki Tomiyama; Tohru Ohnuma; Bolati Kuerban; Katrin Tomson; Miwa Komatsu; Hiromi Shimazaki; Nobutaka Hattori; Heii Arai
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-05-18

8.  Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.

Authors:  Michael T Heneka; Elisabet Reyes-Irisarri; Michael Hüll; Markus P Kummer
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

9.  Activation of PPARγ Ameliorates Spatial Cognitive Deficits through Restoring Expression of AMPA Receptors in Seipin Knock-Out Mice.

Authors:  Libin Zhou; Tingting Chen; Guoxi Li; Chaoming Wu; Conghui Wang; Lin Li; Sha Sha; Lei Chen; George Liu; Ling Chen
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

Review 10.  Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.